Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 307

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies

Open access
Dixon, W. G., Symmons, D. P. M., Lunt, M., Watson, K. D., Hyrich, K. L., Silman, A. J.·2007·Arthritis & Rheumatism

Abstract

Objective: In a recent observational study, we found that the risk of serious infection following anti–tumor necrosis factor α (anti‐TNFα) therapy in patients with rheumatoid arthritis (RA) was not importantly increased compared with the background risk in routinely treated RA patients with similar disease severity. Observational data sets are, however, subject to a number of important biases related to selection factors for the timing of starting and stopping therapy. Infection risk is also likely to vary with duration of therapy. This study was undertaken to examine the influences of these biases and of the method of analysis on the risk of infection. Methods: We compared the risk of serious infection in 8,659 patients treated with anti‐TNFα with that in 2,170 patients treated with traditional disease‐modifying antirheumatic drugs (DMARDs) recruited to the British Society for Rheumatology Biologics Register. We applied a number of statistical models in which we varied the length of the followup period by using different definitions of the date of discontinuation of treatment and different lag periods of risk following drug cessation. Results: When the at‐risk period was defined as “receiving treatment”, the adjusted incidence rate ratio comparing patients receiving anti‐TNFα therapy with patients receiving DMARD therapy was 1.22 (95% confidence interval [95% CI] 0.88–1.69). Limiting followup to the first 90 days, however, revealed an adjusted incidence rate ratio of 4.6 (95% CI 1.8–11.9). Rates of infection were increased in the 90 days immediately following drug discontinuation and beyond, explained by selection factors for drug discontinuation. Conclusion: These findings show that overall, the way in which UK rheumatologists select patients for starting and discontinuing anti‐TNFα therapy explains our previous finding of no increase in risk. However, there may be important increases in true risk, notably early in the course of treatment, that would become more evident depending on the definition of at‐risk period.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.22808

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 307

Metadata

Authors
Dixon, W. G., Symmons, D. P. M., Lunt, M., Watson, K. D., Hyrich, K. L., & Silman, A. J.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2007-08-30
Volume
56
Issue
9
Pages
2896-2904
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2120772714
Cited by
307
References
8
FWCI
17.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. https://app.cochat.ai/papers/10.1002/art.22808
The paper
Dixon, W. G., Symmons, D. P. M., Lunt, M., Watson, K. D., Hyrich, K. L., & Silman, A. J. (2007). Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis & Rheumatism. https://doi.org/10.1002/art.22808

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.